Teleflex has appointed Jason Weidman as President and Chief Executive Officer, effective June 8, placing a longtime Medtronic executive at the helm as the company reshapes its portfolio around higher-focus medtech markets. Weidman spent nearly two decades at Medtronic, most recently serving as SVP and President of the Coronary & Renal Denervation and Aortic, Peripheral, and Venous businesses. He succeeds Stuart Randle, who has served as interim CEO since January and will remain on Teleflex’s Board of Directors. Weidman is also expected to join the board when he assumes the CEO role.
The appointment comes as Teleflex prepares for its next phase following divestitures of its Acute Care, Interventional Urology, and OEM businesses. The company plans to use proceeds from those transactions for a $1 billion share buyback and $800 million debt reduction, giving the incoming CEO a cleaner operating structure and strengthened capital position. Chairman Dr. Stephen Klasko cited Weidman’s experience scaling multi-billion-dollar medtech businesses, launching product innovations, and expanding global markets as key to the company’s go-forward strategy.
Weidman brings more than 25 years of medical device experience across coronary, renal denervation, aortic, peripheral vascular, and venous markets. At Teleflex, he will lead a company increasingly centered on interventional, critical care, and high-acuity hospital markets. His appointment gives Teleflex a CEO with large-platform medtech experience as the company moves from portfolio reshaping into execution.